Fischer W, Bodewei R, Satzinger G
Institut für Pharmacokologie und Toxikologie, Universität Leipzig, Federal Republic of Germany.
Naunyn Schmiedebergs Arch Pharmacol. 1992 Oct;346(4):442-52. doi: 10.1007/BF00171088.
Ralitoline, a thiazolidinone derivative chemically distinct from known antiepileptic drugs, possesses remarkable anticonvulsant properties as demonstrated in various animal models of epilepsy. The efficacy of this compound seems to be comparable or even better than that of conventional antiepileptics. In the present study, the activity of ralitoline was investigated in four seizure models in rodents in order to characterize the anticonvulsant profile of action further. In the maximal electroshock seizure test (mice), this compound showed marked anticonvulsant effects (ED50 2.8 mg/kg i.p.). The efficacy of clinically established anti-epileptics was significantly increased when ralitoline was given as co-medication. In the strychnine seizure test (mice), ralitoline (5 and 10 mg/kg) prolonged the latency of tonic seizures as well as the survival time. On the other hand, in the subcutaneous pentylenetetrazol seizure threshold test (mice), this drug revealed limited protective actions at higher doses and increased the effectiveness of ethosuximide. In unrestrained rats with chronically implanted electrodes, ralitoline (5 mg/kg) significantly reduced the duration of electrically-evoked hippocampal discharges and raised the focal stimulation threshold (10 mg/kg). In the rotorod ataxia test (mice), a TD50 value of 14.5 mg/kg i.p. was determined for ralitoline (protective index TD50/MES-ED50 5.2). With regard to the possible mode of action, whole-cell voltage-clamp experiments on cultured neonatal rat cardiomyocytes showed that ralitoline may act specifically on voltage-sensitive sodium channels. The compound inhibited the fast sodium inward current in a frequency- and voltage-dependent manner. In conclusion, the findings confirm the potent anticonvulsant effects of ralitoline, especially against generalized tonic-clonic and complex partial seizures. Moreover, in combination with antiepileptics, an additive synergism can be found at lower concentrations. Regarding the mode of action, this drug was capable of depressing the fast sodium inward current in cultured heart ventricular cells, suggesting that the local anesthetic properties may be important for the anticonvulsant activity of ralitoline.
雷立托林是一种噻唑烷酮衍生物,其化学结构与已知抗癫痫药物不同,在各种癫痫动物模型中均表现出显著的抗惊厥特性。该化合物的疗效似乎与传统抗癫痫药物相当,甚至更好。在本研究中,为了进一步明确雷立托林的抗惊厥作用特征,在四种啮齿动物癫痫模型中对其活性进行了研究。在最大电休克惊厥试验(小鼠)中,该化合物显示出显著的抗惊厥作用(腹腔注射半数有效量为2.8mg/kg)。当雷立托林作为联合用药时,临床常用抗癫痫药物的疗效显著提高。在士的宁惊厥试验(小鼠)中,雷立托林(5mg/kg和10mg/kg)延长了强直性惊厥的潜伏期以及存活时间。另一方面,在皮下注射戊四氮惊厥阈值试验(小鼠)中,该药物在较高剂量时显示出有限的保护作用,并增强了乙琥胺的有效性。在长期植入电极的自由活动大鼠中,雷立托林(5mg/kg)显著缩短了电诱发海马放电的持续时间,并提高了局部刺激阈值(10mg/kg)。在转棒共济失调试验(小鼠)中,雷立托林的腹腔注射半数毒性剂量为14.5mg/kg(保护指数TD50/MES-ED50为5.2)。关于其可能的作用方式,对培养的新生大鼠心肌细胞进行的全细胞膜片钳实验表明,雷立托林可能特异性作用于电压敏感性钠通道。该化合物以频率和电压依赖性方式抑制快速钠内向电流。总之,这些发现证实了雷立托林具有强大的抗惊厥作用,尤其是对全身性强直阵挛性发作和复杂部分性发作。此外,与抗癫痫药物联合使用时,在较低浓度下可发现相加协同作用。关于作用方式,该药物能够抑制培养的心室细胞中的快速钠内向电流,表明局部麻醉特性可能对雷立托林的抗惊厥活性很重要。